Membership Directory

Idenix Pharmaceuticals, Inc.

Category: Drug Development
Phone: 617-995-9800
Fax: 617-995-9801
Website: http://www.idenix.com

Idenix Pharmaceuticals Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments for human viral and other infectious diseases. Idenix has a robust pipeline of agents that it believes will significantly advance the treatment of hepatitis B, hepatitis C and HIV/AIDS. Idenix’s first product, TYZEKA, for the treatment of hepatitis B, was approved by the U.S. Food and Drug Administration in October 2006. The company's lead drug candidate for the treatment of hepatitis C, valopicitabine (NM283), is a first-in-class nucleoside polymerase inhibitor that is in phase II clinical development. Additionally, Idenix's pipeline includes IDX-899, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV, which will enter clinical development in 2007. Building on the company’s expertise in medicinal chemistry and clinical development, Idenix is positioning itself to become a leader in the antiviral pharmaceutical market.

Back to list

Recent Jobs